S100A1

S100A1

A gene on chromosome 1q21 that encodes a member of the S100 family of proteins, which have 2 EF-hand calcium-binding motifs. S100 proteins are localised in the cytoplasm and/or nucleus of a wide range of cells, and involved in regulating cell cycle progression and differentiation and other intracellular activities.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
Among the DGRs, CNTN2, KCNK1 and S100A1 were found common in frontal cortex and hippocampus datasets.
While troponin I is a well-known marker of cardiac injury, S100A1 originates in cardiomyocytes (8) and it is not clear whether its expression correlates with troponin or can be useful as a new marker of cardio-oncology.
MicroRNA-138 regulates hypoxia-induced endothelial cell dysfunction by targeting S100A1. PLoS One 2013;8:e78684.
Donato, "Annexin V, annexin VI, S100A1 and S100B in developing and adult avian skeletal muscles," Neuroscience, vol.
Lovering et al., "S100A1 promotes action potential-initiated calcium release flux and force production in skeletal muscle," American Journal of Physiology Cell Physiology, vol.
Indeed, HMGB1 and the two S100 family proteins, S100B and S100A1, increase the expression of the antiapoptotic protein Bcl-2, in a RAGE-dependent way, favoring neuroblastoma cell survival [17,29].
CacyBP protein could be interacted with S100 protein family including S100A1, S100A6, S100A12, S100B, and S100P.
The partnership includes uniQure's proprietary gene therapy programme for congestive heart failure that is intended to restore the heart's ability to synthesize S100A1, a calcium sensor and master regulator of heart function as well as the potential for target-exclusive collaboration in other disease areas.
The collaboration includes uniQure's gene therapy program for congestive heart failure that aims to restore the heart's ability to synthesize S100A1, a calcium sensor and master regulator of heart function.
Cardiology researchers have demonstrated feasibility, the long-term therapeutic effectiveness and the safety of S100A1 gene therapy in a large animal model of heart failure under conditions approximating a clinical setting.
The panels of antibodies in various combinations included carbonic anhydrase IX, vimentin, cytokeratin 7 (CK7), CKIT, P504S, TFE3, S100A1, CD10, EMA, INI1, PAX2, PAX8, AE1/AE3, CAM5.2, CK20, HMWCK, Melan-A, HMB-45, synaptophysin, chromogranin, and E-cadherin.
Augmentation of Cav1 channel current and action potential duration after uptake of S100A1 in sympathetic ganglion neurons.